| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/06/2006 | WO2005102335A3 Methods of treating sleep disorders |
| 04/06/2006 | WO2005100373A3 Monosaccharide derivatives as anti-cancer and anti-inflammatory agents |
| 04/06/2006 | WO2005100331A3 Antidiabetic agents |
| 04/06/2006 | WO2005099772A3 Methods for preventing or reducing ischemia/reperfusion induced myocardial cell death |
| 04/06/2006 | WO2005097162A3 Steroid sparing agents and their use |
| 04/06/2006 | WO2005096704A3 Cholesterol lowering composition |
| 04/06/2006 | WO2005082386A3 Manganese and iron based compounds for elastogenesis and connective tissue treatment |
| 04/06/2006 | WO2005081687A3 Human hinge core mimetibodies, compositions, methods and uses |
| 04/06/2006 | WO2005074982A3 Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| 04/06/2006 | WO2005074958A3 Use of an extract of pueraria tuberosa for the treatment of diabetes type 2 |
| 04/06/2006 | WO2005074900A3 NOVEL COMBINATION OF ANTICHOLINERGIC AND β MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES |
| 04/06/2006 | WO2005072079A3 Drug coating providing high drug loading and methods for providing the same |
| 04/06/2006 | WO2005068442A3 Isoxazole derivatives and their use as cyclooxygenase inhibitors |
| 04/06/2006 | WO2005058814A3 Biocidal siloxane coating material containing n-halogenated amine and amide functional groups |
| 04/06/2006 | WO2005051092A3 Method of decreasing fat deposits and body weight in mammals and birds |
| 04/06/2006 | WO2005049065A3 Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections |
| 04/06/2006 | WO2005046854A3 A process for the preparation of diphenylmethylsulfinyl derivatives |
| 04/06/2006 | WO2005041937A3 Controlled release sterile injectable aripiprazole formulation and method |
| 04/06/2006 | WO2005041931A3 Pharmaceutical aerosol compositions |
| 04/06/2006 | WO2005039527A3 Extended release pharmaceutical dosage form |
| 04/06/2006 | WO2005037193A8 Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury |
| 04/06/2006 | WO2005026783A3 Method for configuring air-core photonic-bandgap fibers free of surface modes |
| 04/06/2006 | WO2005017127A3 Rna interference compositions and methods |
| 04/06/2006 | WO2005002612A8 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus and insulin resistance |
| 04/06/2006 | WO2004105768A8 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| 04/06/2006 | WO2004084796A3 Compounds for the treatment of flaviviridae infections |
| 04/06/2006 | WO2004076621A3 Compositions of nucleic acids for treating and detecting influenza virus |
| 04/06/2006 | WO2004050837A3 Treatment of dna damage related disorders |
| 04/06/2006 | US20060074991 System and method for generating an amalgamated database |
| 04/06/2006 | US20060074255 3-Methyl-20-epi-vitamin D derivatives |
| 04/06/2006 | US20060074253 Process for the preparation of citalopram |
| 04/06/2006 | US20060074246 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| 04/06/2006 | US20060074244 Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway |
| 04/06/2006 | US20060074239 Method for the catalytic production of hydrocodone and hydromorphone |
| 04/06/2006 | US20060074236 Crystalline cefdinir salts |
| 04/06/2006 | US20060074233 Detect binding with cells transfected with DNA |
| 04/06/2006 | US20060074131 Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof |
| 04/06/2006 | US20060074130 2-{6-[1-Ethyl-3-(4-trifluoromethoxyphenyl)ureido]-5,6,7,8-tetrahydronaphthalen-2-ylsulfanyl}-2-methylpropionic acid; peroxisome proliferator activated receptors agonist; antidiabetic, dietetics, hypotensive and hypoglycemic agent; dyslipidemia |
| 04/06/2006 | US20060074129 Method for obtaining ozonized oils and vegetable fats and use of said products for pharmaceutical and cosmetic purposes |
| 04/06/2006 | US20060074128 Substituted 2-phenyl benzofurans as estrogenic agents |
| 04/06/2006 | US20060074127 anticancer agents; chemotherapeutic selective agents |
| 04/06/2006 | US20060074126 Chroman derivatives, medicaments and use in therapy |
| 04/06/2006 | US20060074125 Novel dithiolopyrrolones with therapeutic activity |
| 04/06/2006 | US20060074124 Using fused ring heterocyclic compounds such as 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxylic acid amide; neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders such as diabetes; inhibitors of the deacetylase SirT1 protein sirtuin |
| 04/06/2006 | US20060074123 Cyclic AMP-specific phosphodiesterase inhibitors |
| 04/06/2006 | US20060074122 e.g., N-butyl-6-chloro-5-phenyl-1H-indazol-3-amine; kinase inhibitor; obesity and stroke; diseases involving phosphorylation of the tau protein such as Alzheimer's disease, Parkinson's disease, frontoparietal dementia |
| 04/06/2006 | US20060074121 Bicyclic and bridged nitrogen heterocycles |
| 04/06/2006 | US20060074120 cyclopent[f]pyrazole derivatives; antiinflammatory agent; autoimmune diseases; side effect reduction, advantages over steroidal glucocorticoid ligands with respect to undesireable side-effects, efficacy, toxicity or metabolism |
| 04/06/2006 | US20060074119 Thiophene compounds |
| 04/06/2006 | US20060074118 1, 2, 4 - Triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same |
| 04/06/2006 | US20060074117 Purification of olmesartan medoxomil |
| 04/06/2006 | US20060074116 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors |
| 04/06/2006 | US20060074115 Novel hexafluoroisopropanol substituted ether derivatives |
| 04/06/2006 | US20060074114 Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids |
| 04/06/2006 | US20060074113 Antitumor, anticancer agents; using a 2-amino-5-phenyl-(1,3,4)thiadiazoline compound |
| 04/06/2006 | US20060074112 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors |
| 04/06/2006 | US20060074111 Chemical compounds |
| 04/06/2006 | US20060074110 Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 04/06/2006 | US20060074109 Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| 04/06/2006 | US20060074108 Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition |
| 04/06/2006 | US20060074107 Pharmaceutically active piperidine derivatives |
| 04/06/2006 | US20060074106 Treatment of inflammatory disorders |
| 04/06/2006 | US20060074105 Substituted quinoline and quinazoline inhibitors of quinone reductase 2 |
| 04/06/2006 | US20060074104 Use of clioquinol for the therapy of alzheimer's disease |
| 04/06/2006 | US20060074103 Cyclic beta-amino acid derivatives as factor Xa inhibitors |
| 04/06/2006 | US20060074102 Kinase inhibitors as therapeutic agents |
| 04/06/2006 | US20060074101 Method of treating post operative nausea and vomiting |
| 04/06/2006 | US20060074100 Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases |
| 04/06/2006 | US20060074099 5-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-ylmethyl]-thiophene-3-carboxylic acid; cell-cell and cell-substrate adhesion inhibitor; industrial scale; cyclization with condensed methylene precursor compound and glycine; separation of enantiomeric mixture |
| 04/06/2006 | US20060074098 Methods of treatment of amyloidosis using ethanolcyclicamine aspartyl protease inhibitors |
| 04/06/2006 | US20060074097 Regulation of mammalian keratinous tissue using hexamidine compositions |
| 04/06/2006 | US20060074096 anti-cell prolifertive agents; 4-(1,2-diethylimidazol-5-yl)-2-{4-[N-(2-ethoxyethyl)sulphamoyl]anilino}pyrimidine; cancers, solid tumours, leukemias, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, hemangioma, nephropathies, atheroma, atherosclerosis, restenosis, autoimmune diseases, inflammation |
| 04/06/2006 | US20060074095 Novel purine derivatives, preparation method and use as medicines |
| 04/06/2006 | US20060074094 Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia |
| 04/06/2006 | US20060074092 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases |
| 04/06/2006 | US20060074091 Nootropic effect enhancer |
| 04/06/2006 | US20060074090 1,2,5-Thiadiazol-3-yl-piperazine therapeutic agents useful for treating pain, depression and anxiety |
| 04/06/2006 | US20060074089 Quinolone analogs |
| 04/06/2006 | US20060074088 Dihydropteridinones for the treatment of cancer diseases |
| 04/06/2006 | US20060074087 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 04/06/2006 | US20060074086 N-(4-{3'-[(3-ethylureido)-methyl]-2-hydroxybiphenyl-4-yl}-4-methylpentyl)-2,2-dimethylpropionamide; pain, gastrointestinal , genitourinary disorders, inflammation, glaucoma, autoimmune diseases, ischemic conditions, and neurodegenerative diseases, for cardioprotection against ischemic |
| 04/06/2006 | US20060074085 Bcl-XL inhibitors; N-{[4-({(1R)-5-(dimethylamino)-1-[(phenylthio)methyl]pentyl}amino)-3-nitrophenyl]sulfonyl}-4-(4-fluorophenyl)piperidine-1-carboxamide; useful for promoting apoptosis; Anticancer agents; autoimmune diseases; antiinflammatory agents |
| 04/06/2006 | US20060074084 Inhibitors of soluble adenylate cyclase |
| 04/06/2006 | US20060074083 Cyclic and acyclic propenones for treating CNS disorders |
| 04/06/2006 | US20060074082 (Arylamidoaryl)cyanoguanidine compounds |
| 04/06/2006 | US20060074081 Progesterone receptor structure |
| 04/06/2006 | US20060074080 Combination product comprising melagatran and an anti-arrhythmic oxabispidenes |
| 04/06/2006 | US20060074079 Solid pharmaceutical formulations comprising Diacereine and Meloxicam |
| 04/06/2006 | US20060074078 Product comprising a transduction inhibitor of heterotrimeric G protein signals combined with another anti-cancer agent for therapeutic use in the treatment of cancer |
| 04/06/2006 | US20060074077 Pharmaceutical composition for the treatment of athetoid movement |
| 04/06/2006 | US20060074076 3-Methyl-5-(4-methyl-piperidine-1-sulfonyl)-benzofuran-2-carboxylic acid cyclo-hexylmethyl-amide; inhibitors of voltage-gated calcium channels, and thus useful for the treatment of diseases, disorders, and conditions including acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine |
| 04/06/2006 | US20060074075 including cystic fibrosis transmembrane conductance regulator ("CFTR"), used for treating genetic disorders; respiratory system disorders |
| 04/06/2006 | US20060074074 Reacting compounds such as 5-(3,4-dimethoxybenzoyl)-2-(1-isopropoxycarbonyloxy-2-methylpropyl)-2-1,2,3-triazole-4-carboxylate with carbonyl compounds, reacting with an alcohol to produce 1-(1-Isopropoxycarbonyloxyethyl)-7,8-dimethoxy-4(5H),10-dioxo-1H-1,2,3-triazolo[4,5-c][1]benzazepine |
| 04/06/2006 | US20060074073 Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor |
| 04/06/2006 | US20060074072 2-[3-(4-chlorophenyl)ureido] N-[4-(2-oxo-2H-pyridin-1-yl)phenyl]-4-methanesulfonylbutyramide; prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors |
| 04/06/2006 | US20060074071 Substituted arylamides |
| 04/06/2006 | US20060074070 1-Methyl, 2-((2-(2-(guanidinoethyl(dimethylammonium)ethyl-)(naphthyl-1,5-ylene)oxymethyl-),6-(1-hydroxyethyl-)carbapen-2-em-3-carboxylate; 1-methylcarbapenems as bactericides; drug resistance; multidrug resistance; methicillin-resistant Staphylococcus aureus (MRSA) and S. epidermidis(MRSE) |
| 04/06/2006 | US20060074069 e.g. (2R-trans) [4-(4-azetidin-3-yl-piperazin-1-yl)-2-benzyl-piperidin-1-yl]-(3,5-bis-trifluoromethyl-phenyl)-methanone;tachykinins, substance P inhibitor; antidepressant, anxiolytic, antiinflammatory agent, cognition activator; neurodegenerative diseases; addiction, sleep, eating disorders |
| 04/06/2006 | US20060074068 Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions |
| 04/06/2006 | US20060074067 8-(3-pyridinyl)-1-azaspiro[4.5]dec-7-ene; neuroprotectant, analgesic; dysfunction of nicotinic cholinergic neurotransmission, dopamine release, nervous system disorders; drug addiction, obesity; side effect reduction on blood pressure, heart rate, gastro-intestinal tract and skeletal muscle |